Autolus Therapeutics Affirms FY2026 Sales Guidance of $140.000M-$150.000M vs $136.669M Est

Benzinga Newsdesk www.benzinga.com Negative 73.7%

Neg 73.7% Neu 0% Pos 0%

Autolus Therapeutics (NASDAQ:AUTL) affirms FY2026 sales outlook from $140.000 million-$150.000 million to $140.000 million-$150.000 million vs $136.669 million estimate.